Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACETNASDAQ:BYSIOTCMKTS:MRVFFNASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.67+0.1%$0.67$0.45▼$1.70$55.42M1.67711,692 shs269,515 shsBYSIBeyondSpring$3.17+1.9%$1.88$0.98▼$3.44$127.80M0.0731,903 shs1.34 million shsMRVFFNuvo Pharmaceuticals$0.98$0.98$0.42▼$1.25$11.17M0.9811,250 shsN/AVRCAVerrica Pharmaceuticals$0.58+1.0%$0.54$0.38▼$8.98$54.09M1.75590,322 shs368,610 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio0.00%-10.70%-6.78%-12.54%-50.00%BYSIBeyondSpring0.00%+13.62%+88.69%+98.13%+11.62%MRVFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VRCAVerrica Pharmaceuticals0.00%-6.15%-5.68%+4.80%-92.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACETAdicet Bio2.0315 of 5 stars3.32.00.00.01.81.70.6BYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVRCAVerrica Pharmaceuticals4.3326 of 5 stars3.13.00.04.73.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio 2.60Moderate Buy$7.501,019.40% UpsideBYSIBeyondSpring 0.00N/AN/AN/AMRVFFNuvo Pharmaceuticals 0.00N/AN/AN/AVRCAVerrica Pharmaceuticals 2.20Hold$8.001,267.99% UpsideCurrent Analyst Ratings BreakdownLatest MRVFF, VRCA, ACET, and BYSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/9/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M2.22N/AN/A$2.26 per share0.30BYSIBeyondSpring$1.75M73.04N/AN/A($0.37) per share-8.57MRVFFNuvo Pharmaceuticals$54.98M0.20$0.09 per share11.09($0.80) per share-1.22VRCAVerrica Pharmaceuticals$7.57M7.15N/AN/A($0.11) per share-5.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$117.12M-$1.30N/AN/AN/AN/A-59.05%-50.66%8/12/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/AMRVFFNuvo Pharmaceuticals-$25.70M-$0.12N/A∞N/A20.88%-1,996.22%14.25%N/AVRCAVerrica Pharmaceuticals-$76.58M-$1.20N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)Latest MRVFF, VRCA, ACET, and BYSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A5/6/2025Q1 2025ACETAdicet Bio-$0.34-$0.31+$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet BioN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A9.349.34BYSIBeyondSpringN/A2.492.49MRVFFNuvo Pharmaceuticals9.972.111.77VRCAVerrica PharmaceuticalsN/A1.341.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%BYSIBeyondSpring40.29%MRVFFNuvo PharmaceuticalsN/AVRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio7.80%BYSIBeyondSpring29.31%MRVFFNuvo Pharmaceuticals7.00%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio9082.71 million76.26 millionOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableMRVFFNuvo Pharmaceuticals10011.40 million10.60 millionNot OptionableVRCAVerrica Pharmaceuticals4092.49 million42.55 millionOptionableMRVFF, VRCA, ACET, and BYSI HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateJune 19 at 2:22 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Consensus PT from AnalystsJune 19 at 1:29 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short InterestJune 18, 2025 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by BrokeragesJune 16, 2025 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's WhyJune 10, 2025 | marketbeat.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 28, 2025 | globenewswire.comWall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to "Hold"May 24, 2025 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by AnalystsMay 24, 2025 | marketbeat.comVerrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in PipelineMay 18, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference CallMay 13, 2025 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comVerrica Pharmaceuticals Reports Quarterly 2025 Financial ResultsMay 13, 2025 | globenewswire.com6VRCA : Earnings Outlook For Verrica PharmaceuticalsMay 13, 2025 | benzinga.comVerrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate UpdateMay 11, 2025 | msn.comVerrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025May 7, 2025 | globenewswire.comVerrica Pharmaceuticals CEO to Present at Citizens Life Sciences ConferenceMay 4, 2025 | msn.comVerrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New YorkApril 30, 2025 | globenewswire.comWhy Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%April 10, 2025 | aaii.comVerrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTHApril 9, 2025 | msn.comIn face of U.S. stock market selloff, shares of West Chester firm are on the riseApril 8, 2025 | bizjournals.comVerrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1April 8, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRVFF, VRCA, ACET, and BYSI Company DescriptionsAdicet Bio NASDAQ:ACET$0.67 +0.00 (+0.15%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.67 0.00 (0.00%) As of 06/20/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.BeyondSpring NASDAQ:BYSI$3.17 +0.06 (+1.93%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.36 +0.19 (+5.96%) As of 06/20/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Nuvo Pharmaceuticals OTCMKTS:MRVFF$0.98 0.00 (0.00%) As of 03/16/2023Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Verrica Pharmaceuticals NASDAQ:VRCA$0.58 +0.01 (+1.04%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.58 +0.00 (+0.03%) As of 06/20/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
